- Home
- PAVM vs ERNA Comparison
PAVM vs ERNA Comparison
Compare PAVM & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | ERNA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAVM | ERNA |
|---|---|---|
| Price | $0.35 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 484.1K | 56.8K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,000.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $1.09 |
| 52 Week High | $1.06 | $14.40 |
Technical Indicators
Market Signals| Indicator | PAVM | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 44.05 |
| Support Level | $0.31 | $1.10 |
| Resistance Level | $0.39 | $1.32 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 53.07 | 41.67 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.